Literature DB >> 9056020

Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

K E Aldridge1, D S Ashcraft.   

Abstract

Bay 12-8039, a new 8-methoxy quinolone, was compared with other agents for activity against clinically relevant anaerobes. Bay 12-8039 inhibited 91 and 96% of the 410 test isolates at 2 and 4 micrograms/ml, respectively. Bay 12-8039 had activity comparable to that metronidazole and overall was at least 16-fold more active than ciprofloxacin, ofloxacin, and cefoxitin, 32-fold more active than cefotetan, and at least 128-fold more active than penicillin G.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9056020      PMCID： PMC163778     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Osteitis cystica tuberculosa multiplex in a patient infected with human immunodeficiency virus.

Authors:  R G Huth; R Acebo; E B Matthew
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

2.  Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production.

Authors:  K E Aldridge; C V Sanders; A C Lewis; R L Marier
Journal:  J Med Microbiol       Date:  1983-02       Impact factor: 2.472

Review 3.  Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.

Authors:  E J Goldstein
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

4.  Properties of a new penicillinase type produced by Bacteroides fragilis.

Authors:  K Sato; Y Matsuura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

5.  A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

Authors:  K E Aldridge; M Gelfand; L B Reller; L W Ayers; C L Pierson; F Schoenknecht; R C Tilton; J Wilkins; A Henderberg; D D Schiro
Journal:  Diagn Microbiol Infect Dis       Date:  1994-04       Impact factor: 2.803

6.  Beta-lactamases in anaerobic bacteria.

Authors:  C E Nord; L Lindqvist; B Olsson-Liljequist; K Tunér
Journal:  Scand J Infect Dis Suppl       Date:  1985

7.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Beta-lactamases of type culture strains of the Bacteroides fragilis group and of strains that hydrolyse cefoxitin, latamoxef and imipenem.

Authors:  A Eley; D Greenwood
Journal:  J Med Microbiol       Date:  1986-02       Impact factor: 2.472
  8 in total
  23 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.

Authors:  J D C Ross; H S Cronjé; T Paszkowski; I Rakoczi; D Vildaite; A Kureishi; M Alefelder; P Arvis; P Reimnitz
Journal:  Sex Transm Infect       Date:  2006-05-24       Impact factor: 3.519

4.  Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors:  E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  The management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes.

Authors:  Simon Matthew Graham; Adelle Fishlock; Peter Millner; Jonathan Sandoe
Journal:  Eur Spine J       Date:  2013-04-01       Impact factor: 3.134

7.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

8.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; M Hudspeth; S Hunt Gerardo; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

9.  Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin.

Authors:  Rudolph S Wagner; David B Granet; Steven J Lichtenstein; Tiffany Jamison; Joseph J Dajcs; Robert D Gross; Paul Cockrum
Journal:  Clin Ophthalmol       Date:  2010-02-02

10.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.